Structure-based identification of potential SARS-CoV-2 main protease inhibitors

Area of Science:

• Computational chemistry and drug discovery.
• Virology and molecular biology.
• Medicinal chemistry.

Background:

• The COVID-19 pandemic necessitates the development of effective antiviral therapies.
• The SARS-CoV-2 main protease (M^pro) is crucial for viral replication and serves as a key drug target.
• Current therapeutic options for COVID-19 remain limited.

Purpose of the Study:

• To identify potential inhibitors of the SARS-CoV-2 main protease (M^pro) using computational methods.
• To evaluate the binding affinity and stability of identified compounds with M^pro.
• To provide promising drug leads for COVID-19 treatment.

Main Methods:

• Structure-based drug design.
• Pharmacophore modeling.
• Virtual high-throughput screening.
• Molecular docking.
• All-atom molecular dynamics simulations.

Main Results:

• Five potential inhibitors of SARS-CoV-2 M^pro were identified.
• Compound 54035018 demonstrated high binding affinity (ΔG_bind -37.40 kcal/mol) and complex stability.
• The identified compounds exhibit drug-likeness properties.

Conclusions:

• The study identified promising small molecules as potential inhibitors of SARS-CoV-2 M^pro.
• Compound 54035018 is a strong candidate for further investigation.
• Experimental and clinical validation are essential to confirm efficacy for COVID-19 therapy.